Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Share-based Compensation (2020 - 2022)

Historic Share-based Compensation for Atea Pharmaceuticals (AVIR) over the last 3 years, with Q4 2022 value amounting to $11.6 million.

  • Atea Pharmaceuticals' Share-based Compensation rose 259.01% to $11.6 million in Q4 2022 from the same period last year, while for Dec 2022 it was $46.7 million, marking a year-over-year increase of 1791.22%. This contributed to the annual value of $51.8 million for FY2024, which is 473.21% up from last year.
  • Latest data reveals that Atea Pharmaceuticals reported Share-based Compensation of $11.6 million as of Q4 2022, which was up 259.01% from $11.5 million recorded in Q3 2022.
  • In the past 5 years, Atea Pharmaceuticals' Share-based Compensation ranged from a high of $11.9 million in Q2 2022 and a low of $189000.0 during Q1 2020
  • For the 3-year period, Atea Pharmaceuticals' Share-based Compensation averaged around $7.8 million, with its median value being $10.5 million (2021).
  • Its Share-based Compensation has fluctuated over the past 5 years, first soared by 468803.83% in 2021, then skyrocketed by 259.01% in 2022.
  • Quarter analysis of 3 years shows Atea Pharmaceuticals' Share-based Compensation stood at $2.8 million in 2020, then skyrocketed by 302.38% to $11.4 million in 2021, then grew by 2.59% to $11.6 million in 2022.
  • Its Share-based Compensation was $11.6 million in Q4 2022, compared to $11.5 million in Q3 2022 and $11.9 million in Q2 2022.